The EORTC study also evaluated the immunohistochemical profile of the initial and subsequent DCIS and found 63% agreement with staining for oestrogen and progesterone receptors, p53 and HER2/neu oncoprotein (Bijker et al, 2001b). This evidence concerns the gene TP53 and ductal breast carcinoma in situ.